CRYOPORT, INC. Available-for-sale Securities, Gross Unrealized Loss
CRYOPORT, INC. (CYRX) reported Available-for-sale Securities, Gross Unrealized Loss of $30.47 thousand for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2018-11-08
- 2018-09-30: Available-for-sale Securities, Gross Unrealized Loss 9 month $30.47K.
- 2017-09-30: Available-for-sale Securities, Gross Unrealized Loss 9 month $0.00.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 9 month |
|---|---|
| 2018-09-30 | $30.47K 10-Q · filed 2018-11-08 |
| 2017-09-30 | $0.00 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |